Novartis gets indacaterol complete response

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA issued a complete response letter for indacaterol ( QAB149) as a once-daily bronchodilator for maintenance treatment of airflow obstruction in patients with c...